Posted by Michael Wonder on 31 Mar 2026
Zymeworks receives US FDA fast track designation for ZW191, a folate receptor alfa targeting antibody drug conjugate
30 March 2026 - Zymeworks today announced that the US FDA has granted fast track designation to ZW191, an antibody drug conjugate targeting folate receptor alfa, for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer.
ZW191 is an antibody drug conjugate engineered to target folate receptor alfa, a protein expressed in several tumour types, including approximately 75% of high-grade serous ovarian carcinomas, over 50% of endometrial cancers, and ~70% of lung adenocarcinomas.
